Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SI | P14410 | 1/20 | 0.44 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13435847 | 1.00 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4548427 | 0.84 | TSHR (0.37) | ALDH1A1TSHRTDP1LMNA | |
| SCHEMBL27163809 | 0.82 | TSHR (0.53) | GAAALDH1A1TSHRTDP1HSD17B10 | |
| SCHEMBL3336259 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL13319194 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL10405814 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3332151 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL27163257 | 0.80 | L3MBTL1 (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6118705 | 0.79 | GAA (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL28014172 | 0.79 | MGAM (0.40) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116284527-A | Ultrahigh molecular weight polyolefin and preparation method thereof | 中国石油化工股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-10934531-B2 | Method for enantioselective carbene C—H insertion using an iron-containing protein catalyst | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2021-03-02 | — | — | US | disclosed |
| US-20190276805-A1 | METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-12 | — | — | US | disclosed |
| WO-2019147865-A1 | A METHOD FOR ENANTIOSELECTIVE CARBENE C-H INSERTION USING AN IRON-CONTAINING PROTEIN CATALYST | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-08-01 | — | — | WO | disclosed |
| EP-2721053-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2721053-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-19 | — | — | EP | disclosed |
| EP-2721053-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2013-06-06 | — | — | US | disclosed |
| WO-2012173983-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-20 | — | — | WO | disclosed |
| US-4999451-A | Process for preparing dihalovinylcyclopropanecarboxylates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-03-12 | — | — | US | disclosed |
| EP-0232712-B1 | PROCESS FOR THE PREPARATION OF NITRILES | BASF Aktiengesellschaft (DE) | 1990-09-26 | — | — | EP | disclosed |
| US-4833266-A | Process for preparing dihalovinylcyclopropanecarboxylates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1989-05-23 | — | — | US | disclosed |
| EP-0232712-A1 | Process for the preparation of nitriles | BASF Aktiengesellschaft (DE) | 1987-08-19 | — | — | EP | disclosed |
| US-4681953-A | Process for preparing dihalovinylcyclopropanecarboxylates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1987-07-21 | — | — | US | disclosed |
| US-4560401-A | USING 3-ALKYL-2-CARBOXYAZETIDINE | SHELL OIL COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4454343-A | Intermediates in a process for preparing dihalovinylcyclopropanecarboxylates | FMC CORPORATION (US) | 1984-06-12 | — | — | US | disclosed |
| US-4214097-A | Process for preparing dihalovinylcyclopropanecarboxylates | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1980-07-22 | — | — | US | disclosed |
| US-3966799-A | FLAVORS FOR FOODS, CHEWING GUM, AND MEDICINES | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130142754-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, GOT1 | MGAM 2291/4885GAA 132/4885SI 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.